Thiogenesis Therapeutics Corp. has seen a notable decline in its stock performance this week, reflecting broader market sentiments.
Thiogenesis Therapeutics Corp. (TTI.V) has experienced a challenging week, with shares closing at C$0.50, marking a 7.41% decline over the past week. The company's recent news and its technical indicators may provide insight into the current state of the stock.
Advertisement
Thiogenesis Therapeutics Corp.
TTI.V
TTI.V
Thiogenesis Therapeutics Corp.
WealthAwesomeMarket cap
$34.99M
52W high
$0.81
52W low
$0.44
1W change
-7.41%
Beta
0.56
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TTI's historical volatility
30-Day Vol
59.3%
Annualized
90-Day Vol
58.8%
Annualized
Trend (90d)
-47.6%
Annualized drift
90d Mean
C$0.42
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.47 | C$0.39 – C$0.58 |
| 60 trading days | C$0.45 | C$0.33 – C$0.60 |
| 90 trading days | C$0.42 | C$0.30 – C$0.60 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should closely monitor Thiogenesis' clinical developments and market trends, particularly as the company advances its drug candidates through clinical trials.
C$0.50 Closing Price, 7.41% Weekly Decline
Thiogenesis' stock has struggled, with a year-to-date decline of 23.08%, reflecting investor caution amid ongoing clinical developments.
Bull case
If Thiogenesis reports positive results from its clinical trials or receives regulatory approvals, it could significantly boost investor confidence and drive the share price higher.
Bear case
On the other hand, continued losses and a lack of significant news could lead to further declines in stock performance, as we've seen in recent weeks.
Recent Price Action
Advertisement
Thiogenesis Therapeutics Corp. (TTI.V) closed at C$0.50, reflecting no change in price for the day. However, the stock has experienced a significant decline of 7.41% over the past week and is down 9.09% over the last month. Year-to-date, the stock has decreased by 23.08%, indicating a challenging period for the company.
Company News and Web Headlines
This week, there were no major announcements from Thiogenesis. However, previous reports highlighted important milestones, including the FDA's clearance of its Investigational New Drug application for TTI-0102, aimed at treating Leigh syndrome spectrum. The company has also initiated a Phase 2 clinical trial in mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), which could positively impact future performance.
Technical Picture
Analyzing the technical indicators, Thiogenesis is currently trading below its 50-day moving average of C$0.54 and its 200-day moving average of C$0.56, indicating bearish sentiment. The stock has a 52-week range of C$0.44 to C$0.81, with only 16% of this range utilized. The beta of 0.56 suggests lower volatility compared to the broader market. Additionally, the trading volume is significantly below the 20-day average, with the latest volume at 11,500 shares, compared to an average of 32,788 shares.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
